摘要
目的:研究乳腺癌中EZH2和p53表达及其相关性。方法:用免疫组织化学方法检测54例乳腺癌组织中EZH2和p53的表达情况,分析与临床病理特征之间的关系并探讨二者的相关性。结果:乳腺癌中EZH2表达阳性率48%(26/54),EZH2表达与肿瘤大小、淋巴结转移、病理分级、ER受体相关,而与年龄、临床分期、PR受体不相关。在p53阳性的25例乳腺癌患者中,16例EZH2表达阳性,表达率64%(16/25),p53阴性表达的29例中,9例EZH2表达阳性,表达率31%(9/29),两者比较有相关性(P=0.03)。结论:EZH2在乳腺癌中表达增加且与p53相关,提示乳腺癌中EZH2与p53可能相互协调,促进乳腺肿瘤的发生发展。
Objective: To investigate the expression of EZH2 and p53 in human breast carcinoma and their correlation with tumor progression. Method: A total of 44 cases of breast eaneer lumor tissue were detected for the expression of EZH2 and p53 by immunohistochemistry, and fl,rther analyzed their relationship and correlation with the clinical pathologie characterislics. Results: The EZH2 expression was detected in 48% (26/54) of lumor tissues and it's expression was correlaled with the tumor size, lymph node metastasis, pathological grade and Estrogen Receptor(ER) level. In contrast, it did not show correlation with patient age, clinical stage and Progesteron Reeeptor (PR) level. The incidence of EZH2 expression in p53 positive group and p53 negative group was 64% (1.6/25) and 31%(9/29) respectively and this difference between two groups showed statistically significant(P=0.03). Conclusion: EZH2 was over-expressed in breast carcinoma and its over-expression was correlates with expression of p53, which suggested that erosslalk between EZH2 and p53 may play an important role in tumorigenesis and metastasis in breast cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第16期931-933,共3页
Chinese Journal of Clinical Oncology
基金
河北省科学技术研究与发展基金资助(编号:062761995)